Influenza antivirals currently in late-phase clinical trial

Synthesis and pre-clinical studies of new amino-acid ester thiazolide prodrugs

(2017) Andrew V. Stachulski et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Two Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single-Ascending-Dose Studies To Investigate the Safety, Tolerability, and Pharmacokinetics of an Anti-Influenza A Virus Monoclonal Antibody, MHAA4549A, in Healthy Volunteers

(2016) Jeremy J. Lim et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

The Hemagglutinin Stem-Binding Monoclonal Antibody VIS410 Controls Influenza Virus-Induced Acute Respiratory Distress Syndrome

(2016) Tatiana Baranovich et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Activities of JNJ63623872 and oseltamivir against influenza A H1N1pdm and H3N2 virus infections in mice

(2016) Donald F. Smee et al.   ANTIVIRAL RESEARCH

Meeting report: 4th ISIRV antiviral group conference: Novel antiviral therapies for influenza and other respiratory viruses

(2016) Jennifer L. McKimm-Breschkin et al.   ANTIVIRAL RESEARCH

Antiviral susceptibility of influenza viruses isolated from patients pre- and post-administration of favipiravir

(2016) Emi Takashita et al.   ANTIVIRAL RESEARCH

JNJ872 inhibits influenza A virus replication without altering cellular antiviral responses

(2016) Yu Fu et al.   ANTIVIRAL RESEARCH

Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2014–2015

(2016) Aeron C. Hurt et al.   ANTIVIRAL RESEARCH

Structure and Function Analysis of an Antibody Recognizing All Influenza A Subtypes

(2016) Nicole L. Kallewaard et al.   CELL

Neuraminidase inhibitors for influenza: a systematic review and meta-analysis of regulatory and mortality data

(2016) Carl J Heneghan et al.   HEALTH TECHNOLOGY ASSESSMENT

Combinations of Oseltamivir and T-705 Extend the Treatment Window for Highly Pathogenic Influenza A(H5N1) Virus Infection in Mice

(2016) Bindumadhav M. Marathe et al.   Scientific Reports

Thiazolides Elicit Anti-Viral Innate Immunity and Reduce HIV Replication

(2016) Daria Trabattoni et al.   Scientific Reports

Safety and Upper Respiratory Pharmacokinetics of the Hemagglutinin Stalk-Binding Antibody VIS410 Support Treatment and Prophylaxis Based on Population Modeling of Seasonal Influenza A Outbreaks

(2016) Andrew M. Wollacott et al.   EBioMedicine

Phase 1 clinical trials of DAS181, an inhaled sialidase, in healthy adults

(2015) Jonathan M. Zenilman et al.   ANTIVIRAL RESEARCH

Neuraminidase inhibitors: who, when, where?

(2015) J.S. Nguyen-Van-Tam et al.   CLINICAL MICROBIOLOGY AND INFECTION

H3N2 Mismatch of 2014–15 Northern Hemisphere Influenza Vaccines and Head-to-head Comparison between Human and Ferret Antisera derived Antigenic Maps

(2015) Hang Xie et al.   Scientific Reports

Synergistic Effect of Nitazoxanide with Neuraminidase Inhibitors against Influenza A VirusesIn Vitro

(2014) Giuseppe Belardo et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Antiviral Susceptibility of Variant Influenza A(H3N2)v Viruses Isolated in the United States from 2011 to 2013

(2014) K. Sleeman et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Preclinical Activity of VX-787, a First-in-Class, Orally Bioavailable Inhibitor of the Influenza Virus Polymerase PB2 Subunit

(2014) Randal A. Byrn et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Nitazoxanide: A first-in-class broad-spectrum antiviral agent

(2014) Jean-François Rossignol   ANTIVIRAL RESEARCH

Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model

(2014) Lisa Oestereich et al.   ANTIVIRAL RESEARCH

Post-exposure efficacy of Oral T-705 (Favipiravir) against inhalational Ebola virus infection in a mouse model

(2014) Sophie J. Smither et al.   ANTIVIRAL RESEARCH

Broadly Neutralizing Influenza Hemagglutinin Stem-Specific Antibody CR8020 Targets Residues that Are Prone to Escape due to Host Selection Pressure

(2014) Kannan Tharakaraman et al.   Cell Host & Microbe

A community cluster of influenza A(H1N1)pdm09 virus exhibiting cross-resistance to oseltamivir and peramivir in Japan, November to December 2013

(2014) E Takashita et al.   Eurosurveillance

Overview of the 3rd isirv-Antiviral Group Conference - advances in clinical management

(2014) Aeron C. Hurt et al.   Influenza and Other Respiratory Viruses

An Investigational Antiviral Drug, DAS181, Effectively Inhibits Replication of Zoonotic Influenza A Virus Subtype H7N9 and Protects Mice From Lethality

(2014) Henju Marjuki et al.   JOURNAL OF INFECTIOUS DISEASES

Efficacy and Safety of Treatment With an Anti-M2e Monoclonal Antibody in Experimental Human Influenza

(2014) Eleanor L. Ramos et al.   JOURNAL OF INFECTIOUS DISEASES

Discovery of a Novel, First-in-Class, Orally Bioavailable Azaindole Inhibitor (VX-787) of Influenza PB2

(2014) Michael P. Clark et al.   JOURNAL OF MEDICINAL CHEMISTRY

Effect of nitazoxanide in adults and adolescents with acute uncomplicated influenza: a double-blind, randomised, placebo-controlled, phase 2b/3 trial

(2014) Jason Haffizulla et al.   LANCET INFECTIOUS DISEASES

Favipiravir: A New Medication for the Ebola Virus Disease Pandemic

(2014) Takashi Nagata et al.   Disaster Medicine and Public Health Preparedness

Favipiravir (T-705), a novel viral RNA polymerase inhibitor

(2013) Yousuke Furuta et al.   ANTIVIRAL RESEARCH

T-705 (Favipiravir) Induces Lethal Mutagenesis in Influenza A H1N1 Viruses In Vitro

(2013) T. Baranovich et al.   JOURNAL OF VIROLOGY

Favipiravir (T-705) inhibits in vitro norovirus replication

(2012) J. Rocha-Pereira et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

A Phase II Study of DAS181, a Novel Host Directed Antiviral for the Treatment of Influenza Infection

(2012) R. B. Moss et al.   JOURNAL OF INFECTIOUS DISEASES

DAS181 treatment of severe parainfluenza type 3 pneumonia in a lung transplant recipient

(2012) D.R. Drozd et al.   Transplant Infectious Disease

Widespread use of neuraminidase inhibitors in Japan

(2011) Norio Sugaya   JOURNAL OF INFECTION AND CHEMOTHERAPY

Community Transmission of Oseltamivir-Resistant A(H1N1)pdm09 Influenza

(2011) Aeron C. Hurt et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Neutralizing Antibody Selected from Plasma Cells That Binds to Group 1 and Group 2 Influenza A Hemagglutinins

(2011) D. Corti et al.   SCIENCE

A Highly Conserved Neutralizing Epitope on Group 2 Influenza A Viruses

(2011) D. C. Ekiert et al.   SCIENCE

In Vitro Antiviral Activity of Favipiravir (T-705) against Drug-Resistant Influenza and 2009 A(H1N1) Viruses

(2010) K. Sleeman et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Phenotypic and genotypic characterization of influenza virus mutants selected with the sialidase fusion protein DAS181

(2010) Gallen B. Triana-Baltzer et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

New Class of Monoclonal Antibodies against Severe Influenza: Prophylactic and Therapeutic Efficacy in Ferrets

(2010) Robert H. E. Friesen et al.   PLoS One

Human antibodies reveal a protective epitope that is highly conserved among human and nonhuman influenza A viruses

(2010) Andres G. Grandea et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

DAS181 Inhibits H5N1 Influenza Virus Infection of Human Lung Tissues

(2009) R. W. Y. Chan et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Emergence and spread of oseltamivir-resistant A(H1N1) influenza viruses in Oceania, South East Asia and South Africa

(2009) Aeron C. Hurt et al.   ANTIVIRAL RESEARCH

DAS181, a sialidase fusion protein, protects human airway epithelium against influenza virus infection: an in vitro pharmacodynamic analysis

(2009) Gallen B. Triana-Baltzer et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Thiazolides, a New Class of Anti-influenza Molecules Targeting Viral Hemagglutinin at the Post-translational Level

(2009) Jean François Rossignol et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Novel Pandemic Influenza A(H1N1) Viruses Are Potently Inhibited by DAS181, a Sialidase Fusion Protein

(2009) Gallen B. Triana-Baltzer et al.   PLoS One

T-705 (favipiravir) activity against lethal H5N1 influenza A viruses

(2009) M. Kiso et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Potential for Hepatitis C Virus Resistance to Nitazoxanide or Tizoxanide

(2008) B. E. Korba et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Heterosubtypic Neutralizing Monoclonal Antibodies Cross-Protective against H5N1 and H1N1 Recovered from Human IgM+ Memory B Cells

(2008) Mark Throsby et al.   PLoS One

Nitazoxanide, tizoxanide and other thiazolides are potent inhibitors of hepatitis B virus and hepatitis C virus replication

(2007) Brent E. Korba et al.   ANTIVIRAL RESEARCH